The Life Sciences team advised the underwriters of Arvinas’ $120 initial public offering. The offering consisted of 7,500,000 shares of its common stock at a public offering price of $16.00 per share. Goldman Sachs & Co. LLC, Citigroup Global Markets Inc., and Piper Jaffray & Co acted as joint book-running managers for the offering.
Arvinas Inc. is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies to degrade disease-causing proteins.
The Goodwin team was led by partners Robert Puopolo and Seo Salimi and included partners Roger Cohen, Duncan Greenhalgh, Sarah Bock, Caroline Bullerjahn, Janet Andolina and Martin Carmichael; counsel Stephanie Philbin; and associates William Magioncalda, Yasee Zahedi, Steven Tjoe, Bryna Shmerling, Olivia Uitto and Andrew Wilson.For additional information on the offering, please read the press release.